NCT05445011View on ClinicalTrials.gov

Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

June 14, 2025

Study Completion Date

June 14, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Fludarabine + Cyclophosphamide + TAA05 Cell Injection

Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.

Trial Locations (1)

430022

RECRUITING

Wuhan Union Hospital, Wuhan

Sponsors
All Listed Sponsors
collaborator

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER